Viewing Study NCT05328089



Ignite Creation Date: 2024-05-06 @ 5:28 PM
Last Modification Date: 2024-10-26 @ 2:30 PM
Study NCT ID: NCT05328089
Status: RECRUITING
Last Update Posted: 2024-01-03
First Post: 2022-01-15

Brief Title: Vacuolar ATPase and Drug Resistance of High Grade Gliomas
Sponsor: University of Milano Bicocca
Organization: University of Milano Bicocca

Study Overview

Official Title: Vacuolar ATPase and Drug Resistance of High Grade Gliomas a Study to Investigate Possible Therapeutic Roles for Proton Pump Inhibitors
Status: RECRUITING
Status Verified Date: 2023-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: GLIODRUG-V
Brief Summary: GBMs are still considered tumors with few available treatment options that are able only to achieve a temporary local control of the disease In case of a GBM tumor recurrence is generally expected within 12 months and it is due to the presence of marginal tumoral cells with pro-oncogenic molecular phenotypes that are resistant to actual chemotherapies and to radiation therapy Nowadays surgery still represent the first treatment option in case of suspected GBM and it aims to remove the contrast enhancing lesion seen at the pre-operative brain MRI In particular the peripheral layer of the tumor is made of low replicating cellsglioblastoma-associated stromal cell GASC that can show different carcinogenic properties and that are probably responsible for tumor recurrence Metabolism of GBMs is mainly anaerobialglicolisis that leads to the transformation of glucose in ATP and lactates The production of high lactate levels determines a decrease of intracellular pH that is counterbalanced by V-ATPase activity through H ions extrusion from the intracellular to the extracellular environment Increased V-ATPase activity affects different pro-tumoral activities and plays a crucial role in chemoresistance In fact a low extracellular pH can reduce the efficacy of antineoplastic agents since a low pH might affect the structural integrity of drugs and their ability to pass through the plasmatic membrane Finally V-ATPase can act as an active pump able to excrete antineoplastic agents GBMs with high V-ATPAse expression are able to transmit malignant features and to activate proliferation of GASC in vitro through a network of microvescicles MV like exosomes and large oncosomes LO that transport cell to cell copy DNA cDNA and micro-RNAs miRNAIn this view our work is intended to study 1 the effects of proton pump inhibitors PPI on CSC and GASCs cultures as in vitro add-on treatments 2 the MVs load in terms of miRNAs and cDNAs during the neuro-oncological follow-up in order to understand how it changes after surgery and adjuvant treatments 3 the possible roles of V-ATPase as a clinical marker to be used to check tumor response to adjuvant treatments
Detailed Description: GBMs are still considered tumors with few available treatment options that are able only to achieve a temporary local control of the disease In case of a GBM tumor recurrence is generally expected within 12 months and it is due to the presence of marginal tumoral cells with pro-oncogenic molecular phenotypes that are resistant to actual chemotherapies and to radiation therapy In particular in case of GBM it is possible to distinguish three neoplastic layers within the tumor that show different molecular patterns the central core the intermediate layer and the peripheral layer Nowadays surgery still represent the first treatment option in case of suspected GBM and it aims to remove the contrast enhancing lesion seen at the pre-operative brain MRI In particular the peripheral layer is made of low replicating cells and it can be considered normal when tissue sampling is made far from the tumor cavity In fact Clavreul et al in 2015 demonstrated that peripheral GBM layer contains glioblastoma-associated stromal cell GASC that can show different carcinogenic properties and that are probably responsible for tumor recurrence These findings can be considered in line with previous studies that showed some invasive tumor cells various types of reactive cells and angiogenesis with different immunophenotypes in peritumoral brain edema

Nevertheless some research teams are trying to understand if surgical removal of peritumoral FLAIR hyperintensity is able to reduce the tumor recurrence rate prolonging the OS

Metabolism of GBMs is mainly anaerobial and it is sustained by glycolysis Anaerobial glycolysis is a simple metabolic reaction that leads to the transformation of glucose in ATP and lactates Glucose is delivered to the tumor through neoangiogenetic processes Production of a significant amount of lactates determines a decrease of intracellular pH that is counterbalanced by V-ATPase activity through the extrusion of H ions from the intracellular to the extracellular environment In vitro inhibition of V-ATPAse has proved to increase CSC apoptosis due to decrease of intracellular pH

Moreover increased V-ATPase activity determines an extrusion of H ions in the extracellular environment that can positively affect different pro-tumoral activities In fact a decrease of extracellular pH leads to activation of proteases able to destroy the extracellular matrix Such activity enhances tumor spreading Moreover a low extracellular pH can reduce the efficacy of antineoplastic agents since a low pH might affect the structural integrity of drugs and their ability to pass through the plasmatic membrane Finally V-ATPase can act as an active pump able to excrete antineoplastic agents

For this reason PPIs are considered new anti-cancer drugs able to increase tumoral cell death reduce tumor invasion and increase chemotherapy efficacy

Moreover GBMs with high V-ATPAse expression has proved to be able to transmit highly malignant features through a network of MVs and to activate proliferation of GASC in vitro through the transmission of G1 subunit of V-ATPAse

In this view our work is intended to study 1 the effects of PPIs on CSC and GASCs cultures as in vitro add-on treatments 2 the MVs load in terms of miRNAs and DNA ssDNA exoDNA during the neuro-oncological follow-up in order to understand how it changes after surgery and adjuvant treatments 3 the possible roles of V-ATPase as a clinical marker to be used to check tumor response to adjuvant treatments

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None